AlgiKnit Inc. is a biomaterials company integrating science and design into textile production. Addressing the ecological damage caused by the fashion industry, AlgiKnit is creating durable yet rapidly degradable yarns.


Biotia is a health tech company, launched from Cornell Tech and Weill Cornell Medicine, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious disease by deploying the leading reference library of microbes worldwide.

Brooklyn Immuno Therapeutics

Brooklyn ITX is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer. Brooklyn ITX is developing novel immunotherapies based upon reversing immune suppression that is typically seen in patients with cancer and other diseases. The lead product, IRX-2, is a primary cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells, and natural killer cells.

Calder Biosciences

Calder is a private biotechnology company applying proprietary technologies to develop conformationally locked, improved subunit vaccine immunogens. The company’s technologies enhance the performance of these products by stabilizing their conformations, which then better represent the 3-D structure of these proteins on the surface of the pathogen, and therefore give rise to more protective antibody responses. Calder is collaborating with several organizations to develop products and technologies in this space, including the Vaccine Research Center/NIAID, the University of Texas (Austin), PATH, Vanderbilt , the University of Pittsburgh, the University of Miami.

Chemitope Glycopeptide

Chemitope Glycopeptide, LLC, or Chemitope, is a boutique biotech company that aims to produce a new generation of preventative vaccines. Chemitope was founded by Dr. Baptiste Aussedat and Dr. William Walkowicz, two PhD scientists at Memorial Sloan Kettering Cancer Center in New York City, to meet the current and future demand for homogeneous glycopeptides in the ongoing effort to develop an HIV vaccine.

Fork & Goode

Fork & Goode presents a delicious alternative to meeting our meat cravings. Offering delicious flavor, our product is made of real meat, delivering the same essential nutrition with no antibiotics, no hormones, no harmful bacteria, and reduction in harm to animals and the environment, while using only the highest quality natural ingredients. Fork & Goode is addressing high initial costs by using specific and unique innovations to grow cells without need for expensive serum input, increasing cell density using 3D cell growth so costs are spread over a much greater mass of meat, and starting with multiple cell types to achieve both the flavor and nutritional profile of real meat.

International AIDS Vaccine Initiative

IAVI’s AIDS Vaccine Design and Development Laboratory is a versatile facility designed for conducting biological research on novel vaccines. Ongoing work encompasses multiple phases of vaccine development including generation of new vaccines, assessment of vaccine candidates, and generation of supporting technologies needed to advance the most promising candidates to the stage where they can be evaluated in clinical trials. The Lab also collaborates with multiple academic and industry partners to help advance new AIDS vaccine candidates and perform research needed to better understand how the immune system responds to HIV infection or immunization with experimental vaccines.

Regen Lab® USA LLC

RegenLab® is recognized as a certified global leader in medical biotechnologies, specializing in cellular therapies. RegenLab® is at the forefront of innovation, with an expertly designed medical device for the preparation of platelet rich plasma from the patient's own blood. Regen® A-PRP® was developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.